Episode
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates
- Podcast
- Lung Cancer Update
- Published
- Jul 17, 2025
- Duration seconds
- 5321
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-update-827388/episodes/lung-cancer-proceedings-from-a-session-held-during-the-2025-asco-annual-meeting-on-the-current-and-future-role-of-immunotherapy-and-antibody-drug-conjugates/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-update-827388/lung-cancer-proceedings-from-a-session-held-during-the-2025-asco-annual-meeting-on-the-current-and-future-role-of-immunotherapy-and-antibody-drug-conjugates.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here .